Pei S. Ang
Vigilance & Compliance Branch
Singapore, Singapore
Singapore, Singapore
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Unlocking Potential of Generative Large Language Models for Adverse Drug Reaction Relation Prediction in Discharge Summaries: Analysis and Strategy.
Journal: Clinical pharmacology and therapeutics
Published: June 29, 2025
A Mixed-Methods Evaluation to Identify Industry Knowledge Needs and Challenges in Health Product Defect and Recall Reporting in Singapore.
Journal: Drug safety
Published: March 11, 2025
Effectiveness of Transformer-Based Large Language Models in Identifying Adverse Drug Reaction Relations from Unstructured Discharge Summaries in Singapore.
Journal: Drug safety
Published: January 27, 2025
Classification of health product defect reports by deep learning.
Journal: Scientific reports
Published: January 20, 2025
Validation of a Major and Clinically Relevant Nonmajor Bleeding Phenotyping Algorithm on Electronic Health Records.
Journal: Pharmacoepidemiology and drug safety
Published: November 27, 2023
Anaphylaxis post-COVID-19 vaccinations in Singapore.
Journal: Singapore medical journal
Published: October 27, 2023
Automated Classification of Quality Defect Issues Relating to Substandard Medicines Using a Hybrid Machine Learning and Rule-Based Approach.
Journal: Drug safety
Published: July 25, 2023
An updated analysis on myocarditis and pericarditis cases reported following mRNA SARS-CoV-2 vaccination in Singapore.
Journal: Singapore medical journal
Published: April 14, 2023
Combining Machine Learning with a Rule-Based Algorithm to Detect and Identify Related Entities of Documented Adverse Drug Reactions on Hospital Discharge Summaries.
Journal: Drug safety
Published: May 29, 2022
A risk classification model for prioritising the management of quality issues relating to substandard medicines in Singapore.
Journal: Pharmacoepidemiology and drug safety
Published: November 19, 2021
Applying the OMOP Common Data Model to Facilitate Benefit-Risk Assessments of Medicinal Products Using Real-World Data from Singapore and South Korea.
Journal: Healthcare informatics research
Published: October 18, 2021
Last Updated: 09/26/2026